2,176 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by ZEGA Investments LLC

ZEGA Investments LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,176 shares of the medical research company’s stock, valued at approximately $599,000.

Other hedge funds also recently modified their holdings of the company. Millstone Evans Group LLC purchased a new stake in Amgen in the 4th quarter worth approximately $179,000. Summit Global Investments acquired a new stake in shares of Amgen during the fourth quarter worth $3,690,000. Sector Gamma AS boosted its holdings in shares of Amgen by 187.5% during the fourth quarter. Sector Gamma AS now owns 46,000 shares of the medical research company’s stock worth $11,989,000 after purchasing an additional 30,000 shares during the last quarter. TD Private Client Wealth LLC grew its position in shares of Amgen by 4.6% in the fourth quarter. TD Private Client Wealth LLC now owns 22,638 shares of the medical research company’s stock valued at $5,900,000 after purchasing an additional 996 shares during the period. Finally, Gutierrez Wealth Advisory LLC acquired a new position in Amgen in the fourth quarter valued at $318,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Up 0.3 %

Shares of NASDAQ:AMGN opened at $316.04 on Friday. The firm has a market cap of $169.78 billion, a PE ratio of 41.86, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The company has a fifty day simple moving average of $297.24 and a 200 day simple moving average of $299.02. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.01%. Amgen’s dividend payout ratio (DPR) is 126.09%.

Wall Street Analysts Forecast Growth

Several analysts have commented on AMGN shares. Citigroup restated a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Wells Fargo & Company restated an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Leerink Partners dropped their price target on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Piper Sandler lifted their price target on shares of Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Finally, UBS Group restated a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $314.04.

Insiders Place Their Bets

In other Amgen news, EVP David M. Reese sold 25,225 shares of the business’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now owns 36,922 shares in the company, valued at approximately $11,240,533.68. The trade was a 40.59 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock valued at $20,644,335 over the last quarter. Insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.